TIAA CREF Investment Management LLC increased its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 56.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,132,003 shares of the medical equipment provider’s stock after purchasing an additional 407,066 shares during the quarter. TIAA CREF Investment Management LLC owned about 0.56% of Zimmer Biomet worth $136,599,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Teachers Advisors LLC grew its position in shares of Zimmer Biomet by 43.0% in the fourth quarter. Teachers Advisors LLC now owns 479,376 shares of the medical equipment provider’s stock valued at $57,846,000 after purchasing an additional 144,137 shares in the last quarter. Captrust Financial Advisors purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at $627,000. Perceptive Advisors LLC purchased a new position in Zimmer Biomet during the fourth quarter worth about $24,134,000. Empire Life Investments Inc. grew its position in Zimmer Biomet by 9.3% during the fourth quarter. Empire Life Investments Inc. now owns 423,163 shares of the medical equipment provider’s stock worth $51,063,000 after buying an additional 35,972 shares in the last quarter. Finally, Two Sigma Advisers LP grew its position in Zimmer Biomet by 823.1% during the fourth quarter. Two Sigma Advisers LP now owns 739,522 shares of the medical equipment provider’s stock worth $89,238,000 after buying an additional 659,412 shares in the last quarter. Institutional investors own 86.64% of the company’s stock.
In other news, VP Chad F. Phipps sold 20,826 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $115.95, for a total value of $2,414,774.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bryan C. Hanson bought 25,077 shares of the stock in a transaction dated Tuesday, February 20th. The stock was bought at an average cost of $119.68 per share, with a total value of $3,001,215.36. The disclosure for this purchase can be found here. 1.07% of the stock is currently owned by corporate insiders.
Zimmer Biomet Holdings Inc (ZBH) opened at $116.83 on Friday. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The company has a quick ratio of 0.81, a current ratio of 1.50 and a debt-to-equity ratio of 0.76. The stock has a market capitalization of $23,548.79, a PE ratio of 14.44, a PEG ratio of 2.02 and a beta of 1.13.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The firm had revenue of $2.07 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period in the prior year, the business earned $2.14 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.8 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.82%. The ex-dividend date of this dividend is Wednesday, March 28th. Zimmer Biomet’s payout ratio is currently 10.65%.
Several equities analysts recently commented on ZBH shares. Zacks Investment Research cut Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday, November 20th. Canaccord Genuity restated a “hold” rating and set a $125.00 target price on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Goldman Sachs upgraded Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 target price for the company in a research report on Tuesday, December 19th. Oppenheimer restated a “buy” rating on shares of Zimmer Biomet in a research report on Tuesday, December 19th. Finally, Wells Fargo upgraded Zimmer Biomet from a “market perform” rating to an “outperform” rating in a research report on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Zimmer Biomet presently has a consensus rating of “Buy” and an average price target of $140.63.
ILLEGAL ACTIVITY NOTICE: “TIAA CREF Investment Management LLC Buys 407,066 Shares of Zimmer Biomet Holdings Inc (ZBH)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/03/17/tiaa-cref-investment-management-llc-buys-407066-shares-of-zimmer-biomet-holdings-inc-zbh.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.